Quarterly report pursuant to Section 13 or 15(d)

Description of the Business and Financial Condition (Details)

v3.23.2
Description of the Business and Financial Condition (Details)
$ in Thousands
 1 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2021
USD ($)
shares
Jun. 30, 2023
USD ($)
company
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
investor
Jan. 29, 2020
investor
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of pharmaceutical and biotech companies (more than) | company   50        
Cumulative deficit   $ 163,028   $ 150,367    
Net cash used in operations   10,755 $ 9,250 16,200    
Secured convertible notes   9,921   $ 9,893    
IPO            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Public offering (in shares) | shares 2,127,660          
Net proceeds from offering $ 46,800          
Security Purchase Agreement | 2020 Secured Notes            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument, number of investors | investor         2  
Secured convertible notes         $ 25,000  
Security Purchase Agreement | Convertible Debt            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Secured convertible notes         $ 15,000  
Security Purchase Agreement | Convertible Debt | First Closing Notes            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument, number of investors | investor           2
Secured convertible notes   100        
Security Purchase Agreement | Convertible Debt | First Closing Notes | Investor            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Secured convertible notes   $ 10,000